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Trial DesignDesign and rationale for the Influenza
vaccination After Myocardial Infarction (IAMI)
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(AMI) is increased following influenza infection. Small randomized trials, underpowered for clinical end points, indicate that
future cardiovascular events can be reduced following influenza vaccination in patients with established cardiovascular
disease. Influenza vaccination is recommended by international guidelines for patients with cardiovascular disease, but uptake
is varying and vaccination is rarely prioritized during hospitalization for AMI.
Methods/design The Influenza vaccination After Myocardial Infarction (IAMI) trial is a double-blind, multicenter,
prospective, registry-based, randomized, placebo-controlled, clinical trial. A total of 4,400 patients with ST-segment elevation
myocardial infarction (STEMI) or non-STEMI undergoing coronary angiography will randomly be assigned either to in-hospital
influenza vaccination or to placebo. Baseline information is collected from national heart disease registries, and follow-up will
be performed using both registries and a structured telephone interview. The primary end point is a composite of time to all-
cause death, a new AMI, or stent thrombosis at 1 year.
Implications The IAMI trial is the largest randomized trial to date to evaluate the effect of in-hospital influenza
vaccination on death and cardiovascular outcomes in patients with STEMI or non-STEMI. The trial is expected to provide highly
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l,atherosclerotic plaques.1 Initiation of the inflammatory
process in atherosclerosis is multifactorial, including
endogenous triggers such as oxidized low-density lipopro-
tein cholesterol. In addition, exogenous pathogens have
been suggested to initiate the inflammatory response.2 Ahttp://dx.doi.org/10.1016/j.ahj.2017.04.003,
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was described in an early study of influenza epidemics from
1915 to 1929 including the 1918-1920 pandemic.3
Accumulating observational studies have subsequently
documented similar associations. In a self-controlled case
series study (ie, cases acted as their own control in periods
when not exposed) of more than 22,000 patients, the risk
for acutemyocardial infarction (AMI) during the first 3 days
after medical contact for acute respiratory infection was
significantly increased (incidence ratio 4.19, 95% CI
3.18-5.53).4 In a case-control study of more than 11,000
cases of AMI and an equal number ofmatched controls, the
adjusted odds ratio for AMI risk in the 7 days following
respiratory infection was 2.10 (95% CI 1.38-3.21), and the
risk of stroke was doubled.5
Whether influenza vaccination protects against future
cardiovascular events was investigated in a self-controlled
case-series study of more than 8,000 patients diagnosed
with AMI and vaccinated against influenza 1 or more times
during a 6-year study period.6 The incidence of AMI was
significantly reduced in the 60 days following vaccination,
and this was more pronounced for early seasonal
vaccinations before mid-November. In an Australian study
of 275 cases of inpatients with AMI and outpatient controls
without AMI, influenza (positive influenza antibody titers)
was an unrecognized comorbidity in more cases than
controls but after adjustment for background factors
influenza was not a predictor of AMI.7 However, influenza
vaccinationwas found to be significantly protective against
AMI (odds ratio 0.55, 95% CI 0.15-0.65).
Some prospective randomized clinical trials of influenza
vaccination to patients with coronary artery disease have
been conducted. The FLUVACS study randomized 301
patients (200 with AMI and 101 for whom percutaneous
coronary intervention [PCI] was scheduled) to either
influenza vaccine or a control group.8 The risk of death
due to cardiovascular causes significantly decreased during
a 1-year follow-up period in the intervention compared
with the control group (6% vs 17%, respectively). In the
FLUCAD study, 658 patients with angiographic evidence of
coronary artery disease were randomized to receive either
influenza vaccination or placebo. A significant protective
effect of influenza vaccination was seen against coronary
ischemic events (hazard ratio [HR] 0.54, 95% CI 0.29-0.99)
after a median follow-up of 298 days.9 In a prospective
randomized open trial with blinded end points, 442
patients with acute coronary syndrome (ACS) were
randomized to influenza vaccination or no treatment.10
The primary combined end point of major cardiovascular
events, including death, hospitalization from ACS, hospi-
talization from heart failure, and hospitalization from
stroke, occurred less frequently in the vaccine group
than the control group (9.5% vs 19.3%, unadjustedHR 0.70,
95% CI 0.57-0.86). A meta-analysis of previous randomized
trials in patients with ACS and of randomized trials in
patients of risk for cardiovascular disease comprising a totalof 6,735 patients found that influenza vaccine was
associated with a lower risk of composite cardiovascular
events (2.9% vs 4.7%, risk ratio 0.64, 95% CI, 0.48-0.86).11
Thepathophysiological background for a putative benefit
of influenza vaccination in ACS may comprise protective
effects from inflammation, anticoagulant effects, and
prevention of increased metabolic demand with infection.
It is conceivable that influenza increases cytokine produc-
tion, leading to plaque destabilization,12 plaque rupture,13
and triggering of the coagulation cascade.14 B cellsmayplay
a role in atherogenesis,15 and the humoral response
following an influenza vaccination stimulus involves
multiple B-cell subsets, generating a multifaceted humoral
response that provides protective antibodies16 which
might contribute to the possible protection against ACS.
The scientific community strongly advocates that a
sufficiently powered prospective randomized clinical
trial on influenza vaccination as secondary prevention
in cardiovascular disease is carried out.2,4,8,9,17 The need
for such a study was highlighted in a Cochrane review
concluding that additional higher-quality evidence is
necessary to confirm whether influenza vaccination is
effective in preventing cardiovascular disease.18
In the Swedish Coronary Angiography and Angioplasty
Registry, detailed information on all patients undergoing
coronary angiography in Sweden is registered, and similar
registries exist in Denmark (Western Denmark Heart
Registry) and Norway (NORIC). Although registry and
database information by nature is retrospective, we will
in the present study use national registries as prospective
platforms for conducting a randomized clinical multicen-
ter trial, the rationale being that with standardized and
validated information coupled to health care registries by
social security number, almost complete follow-up can be
assured with limited extra work related to conducting a
trial. Another important advantage of using registries as
platforms for randomization is the opportunity to include
a large number of patients over a relatively short time
period, thus allowing investigation of hard end points
such as death, myocardial infarction, stent thrombosis,
revascularization, and stroke. The concept of a
registry-based randomized clinical trial was recently
introduced19,20 and carried out with success in Sweden,
Iceland, and Denmark in the 7,244-patient TASTE trial on
thrombus aspiration in ST-segment elevation myocardial
infarction (STEMI).21 In this study, we use a registry--
based randomized clinical trial design with adjudication
of events to test whether in-hospital influenza vaccina-
tion after ACS protects against future cardiovascular
disease.
Methodology
Hypothesis, and primary and secondary end points
The Influenza vaccination After Myocardial Infarction
(IAMI trial) is a multicenter, prospective, randomized,
Figure 1
Patients with STEMI or NSTEMI referred to coronary angiography
N = 4400
Online 1:1 randomization in registry
Influenza vaccination Placebo vaccination
1 year: Composite of time to all-cause death, new AMI and stent thrombosis + secondary endpoints
2, 3 and 5 years: Exploratory endpoints
trial flow chart
PCI / coronary angiography
Flowchart of study design. Patients with ST-segment elevation myocardial infarction (STEMI) or non-ST- segment elevation myocardial infarction
(NSTEMI) who are undergoing coronary angiography are considered for inclusion in the study. AMI: acute myocardial infarction; PCI:
percutaneous coronary intervention.
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STEMI or non-STEMI (NSTEMI) undergoing coronary
angiography.
We test the hypothesis that influenza vaccination
(Vaxigrip, Sanofi Pasteur) is superior to placebo (saline)
in reducing all-cause death, a new AMI, or stent
thrombosis (first occurring) during the first year after
STEMI or NSTEMI (primary end point). Secondary end
points are each of the components of the end points in
the composite primary end point evaluated separately
and time to cardiovascular death, revascularization,
stroke, rehospitalization for heart failure, and length of
hospital stay at 1 year. All baseline information will be
obtained from coronary angiography and angioplasty
registry databases in which a number of variables are
routinely registered directly in the catheterization labo-
ratory via Web-based interfaces on all patients undergo-
ing coronary angiography and PCI. Clinical end point
parameters will be obtained from continuous national
health registries, from a standard questionnaire (at 7
days), and by a telephone interview (1 year). Patients will
be followed up until 5 years, but end points beyond 1
year will be regarded as exploratory only.
Study population and patient selection
The IAMI study is ongoing in 13 centers in Sweden and
Denmark, and more centers and countries are expected
to join. Recruitment started on October 1, 2016, and is
expected to continue for 3 influenza seasons until March
1, 2019. The final results of the 1-year clinical composite
end point are expected in August 2020.Individuals for inclusion are recruited among patients
referred to the participating centers for coronary angiog-
raphy/PCI because of STEMI or NSTEMI (Figure 1). Patients
will be recruited during the influenza season only (from
October 1 until March 1) and will not receive any
honorarium for participation. STEMI is defined by chest
pain suggestive for myocardial ischemia for ≥30 minutes
and ≤24 hours, and an electrocardiogram with new
ST-segment elevation in ≥2 contiguous leads of ≥0.2 mV
in leads V2-V3 and/or≥0.1 mV in other leads or a probable
new-onset left bundle-branch block. NSTEMI is defined by
a combination of:onset of symptoms such as central chest
pain or aggravated angina pectoris, with or without an
electrocardiographic change with ST-segment lowering or
an inverted T-wave, and rise and/or fall of troponin-T or
troponin-I above the established margin of an AMI. In
addition, referral to coronary angiography/PCI, age ≥18
years, and written informed consent are required for
inclusion.
The exclusion criteria are influenza vaccination within
12 months prior to inclusion or the subject anticipating to
be vaccinated during the current influenza season;
indication for influenza vaccination (as per investigator's
discretion); previous allergic reaction to influenza vaccine;
suspicion of febrile illness or acute; ongoing infection;
hypersensitivity to the active substances or ingredients of
Vaxigrip or against any residues, such as eggs (ovalbumin
or chicken proteins); endogenic or iatrogenic immunosup-
pression that may result in reduced immunization
response; inability to provide informed consent; ageb 18
years; or previous randomization in the IAMI trial.
Figure 2
Flow diagram showing Web-based randomization and relation to national clinical registry.
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The World Health Organization recommends seasonal
influenza vaccination to subjects with chronic medical
conditions (http://www.who.int/mediacentre/factsheets/
fs211/en/). Conducting a randomized clinical trial inwhich
half of the patients will receive placebo might therefore be
considered unethical. However, influenza vaccination of
patients with ischemic heart disease is typically performed
out of hospital and not during hospitalization, and annual
influenza vaccination coverage for the Scandinavian
countries approaches only roughly 50% of target popula-
tions.22 Because the present clinical trial only intends to
include patients not vaccinated within 12 months prior to
inclusion and not considering being vaccinated during the
current influenza season, the trial will increase vaccination
coverage in the target population.
Influenza vaccine can be safely administered to this
patient population. Influenza vaccination shorty follow-
ing PCI was tested in the FLUVACS study where the
majority of patients had a recent STEMI or NSTEMI (N =
200). Vaccination was carried out within 72 hours from
symptom onset without any vaccine-related adverse
events being reported.8 A large case series of more than20,000 persons with a first AMI and 19,000 persons with a
first stroke who received influenza vaccine reported no
increase in the risk of AMI or stroke in the first 3 months
after influenza vaccination.23 Following study inclusion,
some patients could be anticipated to decide to accept
influenza vaccination at a later stage during the same
influenza season. For patients who received active
vaccination as part of the study, additional vaccination
does not impose a health risk.24
The trial is conducted in accordance with the ethical
principles of the Declaration of Helsinki as adopted by the
18th World Medical Assembly in Helsinki, Finland, in
1964 and subsequent versions and has been approved by
the regional ethical review board of Uppsala, Sweden,
and Region Midtjylland, Denmark, and by the Medical
Products Agencies of both countries (EudraCT no.
2014-001354-42). The trial is registered under www.
clinicaltrials.gov: NCT02831608.
Randomization and treatment protocol.
Following informed consent, patients will be random-
ized using an online randomization system. Randomiza-
tion is performed in a 1:1 fashion in blocks by treating
Figure 3
Timing of vaccination (upper panel, dotted line) and follow-up (fu) at 12 months (lower panel). STEMI: ST-segment elevation myocardial infarction;
NSTEMI: non-ST- segment elevation myocardial infarction.
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generated random number list, and patients, investigators,
and all medical staff, except for the unblinded study nurses
administering vaccination, are kept blinded to the alloca-
tion. Because the majority of baseline, procedural, and
outcome information is available from registries in the
participating countries, the accompanying dedicated
electronic case report form is simple with only few
additional questions.
One or more unblinded study nurses at each center, not
otherwise involved or participating in the study, will
prepare the study medication (Vaxigrip/placebo). Placebo
will be obtained from each center's ordinary medical
supply. According to randomization, Vaxigrip is adminis-
tered in a prefilled syringe or the same volume of placebo
(0.5ml sterile sodiumchloride) is drawnup in a syringe just
before the vaccination. A list of information regardingwhat
has been given to each patient (Vaxigrip/placebo) and
when (date and time) is prepared, signed and kept by the
unblinded study nurses. To ascertain blinding, the nurses
will place a piece of foil around the syringe to ensure that
the patient cannot see what is administered during the
vaccination. The influenza vaccination, or placebo, is
administered up to 72 hours following coronary
angiography/PCI (Figure 3). In the early phase of the
study NSTEMI patients were allowed to receive vaccine/
placebo 24hours prior to invasive procedure. But since this
strategy could complicate interpretation of events associ-
ated with index invasive procedure of being study-related
or not we amended a 72 hour post-procedure vaccination
window for all patients to the protocol. Patients will be
observed for 20 minutes after vaccination/placebo to
monitor, and potentially treat, side effects. The influenza
vaccine (Vaxigrip, Sanofi Pasteur - suspension for injection
in pre-filled syringe) may be administered as a deep
subcutaneous injection which is chosen to minimize the
risk of bleeding. Lifelong low-dose aspirin is encouragedbut will be according to national and local clinical routine.
Also, duration of P2Y12 inhibitor treatment and other
pharmacological therapies are left to the discretion of the
treating physician.
Demographic data and procedure-related data are
entered into the national coronary angiography registries
which are coupled to national health quality registries via
personal identification numbers. Data entered at study
inclusion will be used for analysis. Patients in the study will
not attend any follow-up visits (except for patients in the
immunogenicity sub-study). At 7 days after the vaccination
patients will be requested to return a postage paid standard
questionnaire to asses if any adverse event has occurred
following vaccination (Online Table). The end points will
be monitored using national health quality registries.
Moreover, a 12 month telephone interview with the
patients or first degree relatives will be carried out to
collect information on influenza-like illness, influenza
vaccination andhospitalizationsmissed in registry searches.Primary and secondary end points and end point
definitions
The primary end point is time to all-cause death,
hospitalization for a new myocardial infarction or stent
thrombosis (first occurring) within 1 year. These data will
be obtained from national health registries and the 12
month telephone interview. All primary end points up to
1 year will be adjudicated by a central adjudication
committee.
Secondary end points are:
1. Time to all-cause death at 1 year.
2. Time to cardiovascular death at 1 year.
3. Time to definite stent thrombosis at 1 year.
4. Time to unplanned revascularization at 1 year.
5. Time to hospitalization for AMI at 1 year.
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thrombosis (first occurring) at 1 year.
7. Time to stroke at 1 year.
8. Time to hospitalization for heart failure at 1 year.
9. Length of index hospital stay (safety end point).
From a hypothesis generating perspective we aim to
follow up patients through registries beyond 1 year and
up to 5 years. Because influenza may precipitate plaque
rupture13 it is possible that a single influenza vaccination
in the early phase after an AMI may stabilize non-culprit
coronary plaques.25 End points beyond 1 year will be
regarded as exploratory. New PCIs, aortocoronary bypass
operations and stent thromboses are followed in national
health quality registries.
For the primary end point of death, all reasons for death,
i.e. cardiac, non-cardiac or unknown are used. Myocardial
infarction is registered as International Classification of
Diseases-10 codes I21, I21.4 and I22, heart failure as I50
and stroke as I63.9. A central adjudication will be
performed for all reported primary and secondary end
points for the 1-year follow up according to the 2014 ACC/
AHA key data elements and definitions for cardiovascular
end point events in clinical trials.26 Every site will prepare
source documents for the event for central adjudication by
an independent clinical end point committee blinded to
the patients' assigned treatment.Substudy of vaccine immunogenicity
The primary aim of one substudy in selected centers is
to evaluate the immune response to influenza vaccination
in ACS patients. The geometric mean titer of antibodies
(with 95% CIs) and pre−/post-vaccination ratios are
calculated. Seroconversion rate is defined as at least a
4-fold increase in titer. The secondary aim is to relate the
vaccine response to changes in inflammatory markers
(cytokines, atheroprotective antibodies). The response to
influenza vaccine has been shown to be suboptimal in
elderly (N65 years) compared with younger (b44 years)
individuals.27 Moreover, statins may influence the vac-
cine response.28 In a recent observational study the
antibody response to influenza vaccine was found to be
significantly lower in elderly (N65 years) statin users
compared with non-statin users.29 Blood samples are
taken on two occasions; before vaccination and 4 weeks
(+/− 2–3 days) after vaccination.
Study monitoring and data safety monitoring
Sponsor of the trial is Örebro University Hospital in
Sweden. The sponsor and the primary investigator ensure
the conduct of the trial in accordance with the trial
protocol, national laws, and internationally recognized
GCP guidelines. Monitoring is provided by Avdelningen
för kliniska prövningar, AKP in Örebro, Sweden, a
full-service clinical research organization. Study sites aremonitored to ensure the quality of the data and that the
data are collected in accordance with the study protocol,
principles of GCP, and local legislation. Data acquisition
(electronic case report form, eCRF), merging of data with
national registries and adverse event management is
provided by an accredited clinical research organization,
Lytics (Malmö, Sweden).
A maximum of 3 months following inclusion of the first
1000 patients a data safety monitoring board (DSMB) that
include one infectious disease specialist, one clinical
lecturer in public health and one epidemiologist, will
monitor study end points from a blinded interim analysis.
Variables to be assessed are all-cause death, a new
myocardial infarction and stent thrombosis. Premature
termination of the study will be mandated in the event
that one of the treatment strategies shows statistical
difference at the significance level α = 0.001 for the
composite of time to all-cause death, a new myocardial
infarction or stent thrombosis.30Sample size calculation and statistical analysis
Sample size is calculated on the basis of three smaller
randomized studies,8-10 demographic data from annual
Swedish Coronary Angiography and Angioplasty Registry
reports (accessible at http://www.ucr.uu.se/swedeheart/)
and from the TASTE trial in which the number of high risk
patients included was lower than expected.21 The
combined 1-year primary end point of all-cause death, a
new AMI or stent thrombosis is estimated at 10.0%
(expected survival probability of 0.9) for individuals
randomized to placebo. With a 5% two-sided significance
level we calculated that 386 events would be needed to
have 80% statistical power to detect a 25% reduction of the
primary end point in the influenza vaccination group,
corresponding to a hazard ratio of 0.75.31 With this
estimation 2186 patients are needed per treatment arm,
power calculation utilized with STATA release 14 (College
Station, TX, USA). In order to control for dropouts and
crossing from one group to the other (bothwere negligible
in TASTE), 4400 patients will be included.
The data will be passed on from the participating
centers to Örebro University Hospital where data
management work and statistical analyses will be
performed in collaboration with Lytics which is in charge
of external web-randomization.
The results will be analyzed according to the
intention-to-treat principle, i.e. patients randomized to a
certain group will be followed and assessed irrespectively
of the actual treatment. Differences between groups in
time-to-event end points will be assessed with the
log-rank test. For the primary end point, patients will be
censored at 1 year; analyses at other time points will be
handled in a similar way. Survival probabilities will be
displayed and calculated using Kaplan–Meier methodol-
ogy. HRs with corresponding 95% CIs between study
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model. If violation to proportional hazard assumption is
found time-dependent HR will be calculated and adjust-
ment will be made for stratification variables, center and
STEMI/NSTEMI.
Differences between study groups will be assessed with
unpaired t-tests on original scale or log scale as
appropriate. Ordinal variables will be assessed with
chi-2 test for trend or Mann–Whitney U test and Pearson's
chi-square test or Fisher's exact test will be used to test
differences between proportions. Two-sided statistical
significance levels of 5% will be used and estimates will
be presented with 95% CIs.
Subgroup analyses will first and foremost be carried out
for the primary end point and its components. All
subgroup analyses of event data will be performed
using a proportional hazards model with factors: treat-
ment, subgroup, and treatment-subgroup interaction, and
will be presented with within-group HRs with 95%
confidence intervals and the interaction p-value. The
primary subgroup analyses will focus on the STEMI and
NSTEMI populations and the effect of intervention in
each of the three influenza seasons, with the purpose of
evaluating effect in each subgroup.
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Discussion
In the IAMI study we investigate whether in-hospital
influenza vaccination after AMI protects against future
cardiovascular events. The potential gains of vaccinating
patients with a high risk of future cardiovascular events, a
risk which is pronounced in patients that just suffered an
AMI,32 are considerable. A recent meta-analysis of high
risk patients in 7 case–control studies of more than
17,000 patients found that influenza vaccination reduced
the risk of AMI by 29%.33
Since the possible impact of a simple, safe, inexpensive,
once-per year vaccination seems evident it is notable that
a clinical trial powered for hard clinical cardiovascularend points has not been carried out previously. One
explanation could be that available data suffice. Results
from registry findings, case–control studies and few small
randomized trials suggest that influenza vaccination
protects against cardiovascular disease. Influenza vacci-
nation is guideline recommended by the American Heart
Association and the American College of Cardiology
(Class I, level of evidence B recommendation)34 and “may
be considered” according to The European Society of
Cardiology (Class IIb, level of evidence C).35 When all
available information on the subject was condensed in a
Cochrane review the conclusion was that additional
higher-quality evidence is necessary to confirm whether
influenza vaccination is effective in preventing cardio-
vascular disease.18
In order to navigate between ethics and guidelines on
the one side and a strong wish from the scientific
community to provide more evidence, on the other, the
IAMI trial will only include patients not vaccinated during
the last 12 months and not intending to be vaccinated in
the current influenza season. It is interesting that despite
recommendations and guidelines influenza vaccine up-
take statistics and local practices do not indicate that
influenza vaccine is systematically administered
in-hospital after an ACS. Despite registry findings
implying that a single yearly influenza vaccination may
be as effective as statins after ACS most often vaccination
is usually not performed in the coronary care unit, but in a
primary care setting. Such a practice is likely associated
with reduced compliance36 and the duration between
discharge and influenza vaccination will likely vary. In
IAMI we try to address both issues by recruiting patients
shortly after admission with an ACS – a strategy which
ensures higher patient compliance37 and a well-defined
time interval between ACS and investigational vaccine
administration.
When considering findings from themajority of previous
registry studies on influenza vaccination and cardiovascular
disease the question arises whether results are too good to
be true. Subjects seeking influenza vaccination are typically
healthier, have a higher level of education and are more
concerned about their own well-being than subjects not
being vaccinated.38,39 Such bias in observational studies is
referred to as the healthy user effect (the propensity for
patients who receive one preventive therapy to also seek
other preventive services or partake in other healthy
behaviors) or healthy adherer effect (patients who adhere
to preventive therapy are more likely to engage in other
healthy behaviors than their non-adherent counterparts)40
and is difficult to adjust for statistically. For example,
observational studies have found a decrease in mortality of
more than 50% following influenza vaccination - a benefit
ten times greater than the estimated influenza mortality
burden.41 Also lower rates of conditions not reasonably
related to influenza infection, such as hospitalization for
trauma and injury, have been observed with influenza
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Volume 189vaccination and the beneficial effects were even present
before influenza season.38
Limitations
In the IAMI study we investigate the effect of a single,
standard, trivalent influenza vaccine containing A- and
B-type viral lineages. During the course of the study it is
likely that quadrivalent influenza vaccine will become the
standard and this will introduce heterogeneity when
interpreting the final results.
In a large randomized controlled trial high-dose influenza
vaccine reduced laboratory-confirmed influenza compared
with standard dose influenza vaccine24 and high-dose
influenza vaccine has now been approved in the USA and
Canada for individuals over the age of 65 years. In the
‘INfluenza Vaccine to Effectively Stop CardioThoracic
Events and Decompensated heart failure (INVESTED)’
study (ClinicalTrials.gov number, NCT02787044), intend-
ing to include 9300 patients, the investigators will evaluate
whether a high-dose vaccine strategy compared with a
standard-dose vaccine strategy will be more effective in
reducing cardiopulmonary hospitalization and mortality in
heart failure and post-infarction patients. Since influenza
vaccine/placebo in IAMI is administered in close proximity
to a cardiovascular event, a condition with increased
inflammatory activity, and because we wish to investigate
an approved conventional therapy we chose to adhere to a
standard dose strategy.
IAMI uses a hybrid registry-based randomized clinical
trial methodology42 and a number of variables will be
collected from existing registries and this ensures simplic-
ity and lowers costs. The theoretic downside to this design
is less rigorous validation of variables compared to a
conventional clinical trial. However, the accuracy of the
key parameters of the primary composite end point carries
high accuracy43 and adjudication of registry events and
events unobserved in registries will be carried out after the
12 months telephone follow-up and collection of source
data. The registry-based design was introduced in a 7000+
patient study on thrombus aspiration with STEMI21 and
later indirectly verified in an even larger conventional
clinical trial with very similar outcomes.44
Health care professionals engaged in the IAMI trial are
encouraged to receive influenza vaccination themselves
during the study period but are not obliged to do so.
Transmission of influenza from study health care
professionals to patients thus cannot be excluded.
In conclusion, the IAMI trial is the largest randomized
trial to date to evaluate the effect of in-hospital influenza
vaccination on death and cardiovascular end points in
patients with ACS. The trial is expected to provide
highly relevant clinical data on the efficacy of
in-hospital influenza vaccine as secondary prevention
after AMI.
Supplementary data to this article can be found online
at http://dx.doi.org/10.1016/j.ahj.2017.04.003.References
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